Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (223)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (636)
  2. Solid Tumor Oncology Division (636)
  3. Thoracic Oncology (636)
  4. Department of Pathology and Laboratory Medicine (208)
  5. GSK Faculty (189)
  6. Human Oncology and Pathogenesis Program (158)

More Groups

People
  1. Marc Ladanyi (122)
  2. Mark Kris (90)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (20)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (636)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC)
    Meeting Abstract

    Cabanillas, M. E.; Lin, J. J.; Brose, M. S.; McDermott, R. S.; Almubarak, M.; Bauman, J. R.; Casanova, M.; Kummar, S.; Lee, S. H.; Leyvraz, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Meeting Abstract

    Hong, D. S.; Drilon, A. E.; Tan, D. S. W.; Lin, Jessica J.; Kummar, S.; McDermott, R. S.; Berlin, J.; Italiano, A.; Lassen, U. N.; Leyvraz, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors
    Meeting Abstract

    Gu, S.; Dusza, S. W.; Dunkel, I. J.; Drilon, A. E.; Lacouture, M. E.; Markova, A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions
    Meeting Abstract

    Chen, M. F.; Yang, S. R.; Tao, J.; Desilets, A.; Rosen, E.; Gong, Y.; Mullaney, K. A.; Kris, M. G.; Arcila, M. E.; Donoghue, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort
    Meeting Abstract

    Repetto, M.; Richards, A. L.; Chen, M. F.; Zhu, Y.; Selenica, P.; Gazzo, A.; Lee, P.; Price, A.; Yang, S. R.; Marra, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository
    Meeting Abstract

    Choudhury, N. J.; Harada, G.; Whiting, K.; Shen, R.; Yang, S. R.; Solit, D. B.; Berger, M. F.; Dinapoli, S.; Abou-Alfa, G. K.; Iyer, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Sivaprakasam, K.; Harada, G.; Choudhury, N. J.; Savin, C.; Shah, R. H.; Berger, M. F.; Drilon, A. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors
    Meeting Abstract

    Drilon, A. E.; Johnson, M. L.; Gadgeel, S. M.; Nepert, D.; Feng, G.; Golmakani, M.; Reddy, M.; Harney, A.; Oliver, C.; Mills, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Quantifying the growth of clinical actionability in precision oncology using OncoKB
    Meeting Abstract

    Suehnholz, S. P.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Zhang, H.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save